DAMGO-10 mg

Description

DAMGO is a μ-opioid receptor (μ-OPR ) selective agonist with a Kd of 3.46 nM for native μ-OPR[1].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)–Cancer-programmed cell death–C26H35N5O6—bioRxiv. 2022 Jul 11.|Cell. 2022 Nov 10;185(23):4361-4375.e19.|Cell. 2023 Jan 19;186(2):413-427.e17.-[1]FEBS Lett. 1995 Jan 2;357(1):93-7. Onogi T, et al. DAMGO, a mu-opioid receptor selective agonist, distinguishes between mu- and delta-opioid receptors around their first extracellular loops.|[2]Patel JP, et al. Modulation of neuronal CXCR4 by the micro-opioid agonist DAMGO. J Neurovirol. 2006 Dec;12(6):492-500.|[3]Gold MS, et al. DAMGO inhibits prostaglandin E2-induced potentiation of a TTX-resistant Na+ current in rat sensory neurons in vitro. Neurosci Lett. 1996 Jul 12;212(2):83-6.|[4]Desmeules JA, et al. Selective opioid receptor agonists modulate mechanical allodynia in an animal model of neuropathic pain. Pain. 1993 Jun;53(3):277-285.–78123-71-4–513.59–99.90–OC1=CC=C(C[C@H](N)C(N[C@H](C)C(NCC(N(C)[C@H](C(NCCO)=O)CC2=CC=CC=C2)=O)=O)=O)C=C1–Cancer–DMSO : 33.33 mg/mL (ultrasonic)|H2O : ≥ 100 mg/mL–Opioid Receptor–μ Opioid Receptor/MOR–GPCR/G Protein;Neuronal Signaling–Peptides